Here are four things to know.
1. Admelog was approved to control blood sugar levels after eating in adults and children older than three with Type 1 diabetes as well as adults with Type 2 diabetes.
2. Sanofi’s drug is a biosimilar version of Eli Lilly’s drug Humalog, which earned Eli Lilly $696.2 million in the latest quarter, according to Reuters.
3. The drug is a short-acting insulin. Type 1 diabetics need both a long-acting insulin and short acting insulin.
4. Admelog was approved through the FDA’s abbreviated approval pathway.
More articles on supply chain:
Study: 95.7% of US pharma sales go through primary distributors
10 recent pharma layoffs
Teva considers 10k job cuts to meet cost reduction goal of up to $2B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.